Literature DB >> 2015555

Pyruvate kinase activity and isozyme composition in normal fibrous tissue and fibroblastic proliferations.

J R Elbers1, J A van Unnik, G Rijksen, B A van Oirschot, P J Roholl, J Oosting, G E Staal.   

Abstract

Pyruvate kinase (PK) was studied in 57 fibroblastic and fibrohistiocytic proliferations and normal fibrous tissue (n = 10). The specific activity was significantly increased in malignant tumors (1.67 +/- 0.25) compared with normal tissue (0.26 +/- 0.04; P less than 0.001) and benign proliferations (0.52 +/- 0.05; P less than 0.005). Although an overlap exists between aggressive fibromatosis and the benign group, high values of PK activity are indicative of Grade 2 and 3 malignancy. Significant shifts in isozyme pattern, favoring the expression of K-type subunits were found in tumors with a metastasizing potential and aggressive fibromatosis. These changes in the isozyme pattern of PK in aggressive fibromatosis may act as another argument to place them in the category of malignant fibroblastic tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015555     DOI: 10.1002/1097-0142(19910515)67:10<2552::aid-cncr2820671027>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

2.  Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase.

Authors:  Xueliang Gao; Haizhen Wang; Jenny J Yang; Xiaowei Liu; Zhi-Ren Liu
Journal:  Mol Cell       Date:  2012-02-02       Impact factor: 17.970

Review 3.  Pyruvate kinase M2: A simple molecule with complex functions.

Authors:  Mohammed Alquraishi; Dexter L Puckett; Dina S Alani; Amal S Humidat; Victoria D Frankel; Dallas R Donohoe; Jay Whelan; Ahmed Bettaieb
Journal:  Free Radic Biol Med       Date:  2019-08-08       Impact factor: 7.376

4.  Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition.

Authors:  Atsushi Hamabe; Masamitsu Konno; Nobuhiro Tanuma; Hiroshi Shima; Kenta Tsunekuni; Koichi Kawamoto; Naohiro Nishida; Jun Koseki; Koshi Mimori; Noriko Gotoh; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori; Hideshi Ishii
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

Review 5.  A critical review of the role of M2PYK in the Warburg effect.

Authors:  Robert A Harris; Aron W Fenton
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-01-29       Impact factor: 10.680

6.  PKM2 released by neutrophils at wound site facilitates early wound healing by promoting angiogenesis.

Authors:  Yinwei Zhang; Liangwei Li; Yuan Liu; Zhi-Ren Liu
Journal:  Wound Repair Regen       Date:  2016-03-10       Impact factor: 3.617

7.  Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals.

Authors:  Xueliang Gao; Haizhen Wang; Jenny J Yang; Jing Chen; Jiang Jie; Liangwei Li; Yinwei Zhang; Zhi-Ren Liu
Journal:  J Biol Chem       Date:  2013-04-10       Impact factor: 5.157

8.  Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis.

Authors:  Liangwei Li; Yinwei Zhang; Jingjuan Qiao; Jenny J Yang; Zhi-Ren Liu
Journal:  J Biol Chem       Date:  2014-07-28       Impact factor: 5.157

9.  Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased Pyruvate Kinase M2 (PKM2) Expression in Cervical Cancer Cells.

Authors:  Ke-Yan Cheng; Min Hao
Journal:  Med Sci Monit       Date:  2017-04-27

10.  Rhabdomyosarcoma cells show an energy producing anabolic metabolic phenotype compared with primary myocytes.

Authors:  Teresa W M Fan; Magda Kucia; Kacper Jankowski; Richard M Higashi; Janina Ratajczak; Marius Z Ratajczak; Andrew N Lane
Journal:  Mol Cancer       Date:  2008-10-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.